You can make way cheaper drugs than $1-2 billion (fidaxomicin was developed by Optimer for 200some million) by being very, very picky about your targets, and not failing.

But it's not a trivial thing to disrupt, and there are some costs that are just out and out fixed (clinical trials are spendy).